Literature DB >> 35482422

Lethal synergy between SARS-CoV-2 and Streptococcus pneumoniae in hACE2 mice and protective efficacy of vaccination.

Tarani Kanta Barman, Amit K Singh, Jesse L Bonin, Tanvir Noor Nafiz, Sharon L Salmon, Dennis W Metzger.   

Abstract

Secondary infections are frequent complications of viral respiratory infections, but the potential consequence of SARS-CoV-2 coinfection with common pulmonary pathogens is poorly understood. We report that coinfection of human ACE2-transgenic mice with sublethal doses of SARS-CoV-2 and Streptococcus pneumoniae results in synergistic lung inflammation and lethality. Mortality was observed regardless of whether SARS-CoV-2 challenge occurred before or after establishment of sublethal pneumococcal infection. Increased bacterial levels following coinfection were associated with alveolar macrophage depletion, and treatment with murine GM-CSF reduced numbers of lung bacteria and pathology and partially protected from death. However, therapeutic targeting of IFNs, an approach that is effective against influenza coinfections, failed to increase survival. Combined vaccination against both SARS-CoV-2 and pneumococci resulted in 100% protection against subsequent coinfection. The results indicate that when seasonal respiratory infections return to prepandemic levels, they could lead to an increased incidence of lethal COVID-19 superinfections, especially among the unvaccinated population.

Entities:  

Keywords:  Bacterial infections; Immunology; Infectious disease; Molecular pathology; Mouse models

Mesh:

Year:  2022        PMID: 35482422      PMCID: PMC9220949          DOI: 10.1172/jci.insight.159422

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  54 in total

1.  Local delivery of GM-CSF protects mice from lethal pneumococcal pneumonia.

Authors:  Kathrin Steinwede; Ole Tempelhof; Kristine Bolte; Regina Maus; Jennifer Bohling; Bianca Ueberberg; Florian Länger; John W Christman; James C Paton; Kjetil Ask; Shyam Maharaj; Martin Kolb; Jack Gauldie; Tobias Welte; Ulrich A Maus
Journal:  J Immunol       Date:  2011-10-14       Impact factor: 5.422

2.  Synergistic stimulation of type I interferons during influenza virus coinfection promotes Streptococcus pneumoniae colonization in mice.

Authors:  Shigeki Nakamura; Kimberly M Davis; Jeffrey N Weiser
Journal:  J Clin Invest       Date:  2011-08-15       Impact factor: 14.808

3.  Limited Efficacy of Antibacterial Vaccination Against Secondary Serotype 3 Pneumococcal Pneumonia Following Influenza Infection.

Authors:  Dennis W Metzger; Yoichi Furuya; Sharon L Salmon; Sean Roberts; Keer Sun
Journal:  J Infect Dis       Date:  2015-02-03       Impact factor: 5.226

4.  Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice.

Authors:  Arash Shahangian; Edward K Chow; Xiaoli Tian; Jason R Kang; Amir Ghaffari; Su Y Liu; John A Belperio; Genhong Cheng; Jane C Deng
Journal:  J Clin Invest       Date:  2009-07       Impact factor: 14.808

5.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

Review 6.  Increased antimicrobial resistance during the COVID-19 pandemic.

Authors:  Chih-Cheng Lai; Shey-Ying Chen; Wen-Chien Ko; Po-Ren Hsueh
Journal:  Int J Antimicrob Agents       Date:  2021-03-19       Impact factor: 5.283

7.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

Authors:  Lindsey R Baden; Hana M El Sahly; Brandon Essink; Karen Kotloff; Sharon Frey; Rick Novak; David Diemert; Stephen A Spector; Nadine Rouphael; C Buddy Creech; John McGettigan; Shishir Khetan; Nathan Segall; Joel Solis; Adam Brosz; Carlos Fierro; Howard Schwartz; Kathleen Neuzil; Larry Corey; Peter Gilbert; Holly Janes; Dean Follmann; Mary Marovich; John Mascola; Laura Polakowski; Julie Ledgerwood; Barney S Graham; Hamilton Bennett; Rolando Pajon; Conor Knightly; Brett Leav; Weiping Deng; Honghong Zhou; Shu Han; Melanie Ivarsson; Jacqueline Miller; Tal Zaks
Journal:  N Engl J Med       Date:  2020-12-30       Impact factor: 91.245

8.  Severe Acute Respiratory Syndrome Coronavirus 2-Induced Immune Activation and Death of Monocyte-Derived Human Macrophages and Dendritic Cells.

Authors:  Jian Zheng; Yuhang Wang; Kun Li; David K Meyerholz; Chantal Allamargot; Stanley Perlman
Journal:  J Infect Dis       Date:  2021-03-03       Impact factor: 5.226

9.  A role for Streptococcus pneumoniae in virus-associated pneumonia.

Authors:  Shabir A Madhi; Keith P Klugman
Journal:  Nat Med       Date:  2004-07-11       Impact factor: 53.440

10.  A Mouse Model of SARS-CoV-2 Infection and Pathogenesis.

Authors:  Shi-Hui Sun; Qi Chen; Hong-Jing Gu; Guan Yang; Yan-Xiao Wang; Xing-Yao Huang; Su-Su Liu; Na-Na Zhang; Xiao-Feng Li; Rui Xiong; Yan Guo; Yong-Qiang Deng; Wei-Jin Huang; Quan Liu; Quan-Ming Liu; Yue-Lei Shen; Yong Zhou; Xiao Yang; Tong-Yan Zhao; Chang-Fa Fan; Yu-Sen Zhou; Cheng-Feng Qin; You-Chun Wang
Journal:  Cell Host Microbe       Date:  2020-05-27       Impact factor: 21.023

View more
  1 in total

1.  Complementary Sets of Autoantibodies Induced by SARS-CoV-2, Adenovirus and Bacterial Antigens Cross-React with Human Blood Protein Antigens in COVID-19 Coagulopathies.

Authors:  Robert Root-Bernstein; Jack Huber; Alison Ziehl
Journal:  Int J Mol Sci       Date:  2022-09-29       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.